



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Kukolj & Pause ) Confirm. No.: 9062  
Serial No.: 10/789,355 ) Art Unit: 1648  
Filed: February 27, 2004 ) Examiner: Li, Bao Q.  
For: Self-Replicating RNA Molecule from Hepatitis C Virus  
Docket No.: 13/083-3-D2

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RESPONSE

Sir:

This is in response to a communication received from the Examiner in charge of the subject application, which communication was mailed on October 18, 2005.

The communication mailed October 18<sup>th</sup> comprised a restriction requirement. Applicants, through their attorney, hereby elect for prosecution the invention designated as Group I, claims 1 and 3 through 6 drawn to a HCV polynucleotide comprising one substitution mutation. Additionally, as requested by the Examiner, applicants elect as species G2042C. However, it is respectfully requested that the second mutation G2042R be included in the search, since such mutation is at the same position.

The election is without traverse.

Respectfully submitted,



Mary-Ellen M. Devlin  
Attorney for Applicants  
Reg. No. 27,928


Patent Department  
Boehringer Ingelheim Corp.  
900 Ridgebury Road, P.O. Box 368  
Ridgefield, CT 06877  
Tel: (203) 798-4866

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

on November 16, 2005.



Mary-Ellen M. Devlin, Reg. No. 27,928